Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neogenix Oncology is set to receive European Patent for NEO-301 antibody from the European Patent Office (EPO).
Subscribe to our email newsletter
NEO-301 specifically binds a variant of the A33 tumor antigen which is a target expressed on the majority of colorectal cancers, and was also found to be expressed by other cancers such as pancreatic cancer.
Earlier, the EPO has issued a ‘Decision to Grant’ the company’s patent application, designated as EP Patent no. 02726672.5, on 23 December, 2010.
The application covers NEO-301 in naked and labeled form for use in treating pancreatic cancer as well as medicaments containing this antibody for treating pancreatic cancer.
In addition, the allowed claims broadly cover the use of NEO-301 for diagnosis of pancreatic cancer and in diagnostic kits for detecting pancreatic cancer.
This allowance expands the company’s patent protection relating to NEO-301 which includes US Patent No. 5,688,657 (reissued as RE39, 760) and numerous other pending patent applications.
The patent, which will take effect beginning 23 September 2011, will be in force until 15 March 2022.